Guidelines for the diagnosis and management of alcoholic liver disease: Update 2010: (Published in Chinese on Chinese Journal of Hepatology 2010; 18: 167-170) YM Li etal. Diagnosis and management of ALD

Journal of Digestive Diseases

Volumn 12, Issue 1, 2011, Pages 45-50

  Li, You Ming ^a   Fan, Jian Gao ^c   Wang, Bing Yuan ^e   Lu, Lun Gen ^d   Shi, Jun Pin ^b   Niu, Jun Qi ^f   Shen, Wei ^g  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Hangzhou 6th People's Hospital   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f JILIN UNIVERSITY   (China)

^g CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOHYDRATE DEFICIENT TRANSFERRIN; FOLIC ACID; METADOXINE; PHOSPHATIDYLCHOLINE; PREDNISOLONE; S ADENOSYLMETHIONINE; SILYMARIN; VITAMIN B GROUP; VITAMIN K GROUP;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ALCOHOLIC BEVERAGE; ALCOHOLIC FATTY LIVER; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CACHEXIA; CHINA; CHINESE MEDICINE; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; CRITERION VARIABLE; DIET SUPPLEMENTATION; EPIGASTRIC FULLNESS; FEVER; HEPATIC ENCEPHALOPATHY; HEPATOMEGALY; HUMAN; JAUNDICE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALAISE; MEAN CORPUSCULAR VOLUME; NAUSEA AND VOMITING; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SPLENOMEGALY; TELANGIECTASIA; TRANSFERRIN BLOOD LEVEL; ULTRASOUND; WEAKNESS;

ASIAN CONTINENTAL ANCESTRY GROUP; HUMANS; LIVER DISEASES, ALCOHOLIC; RISK FACTORS;

EID: 79251553133     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00477.x     Document Type: Article

References (49)

1. Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
2. Alcohol Dependence and Liver Disease Questionnaire Collaborative Group. Alcohol dependence collaborative research in four kinds of occupational population in nine Chinese cities. Zhongguo Xinli Weisheng Zazhi 1992; 6: 112 (in Chinese).
3. Li YM, Chen WX, Yu CH etal. An epidemiological survey of alcoholic liver disease in Zhejiang province. Zhonghua Ganzangbing Zazhi 2003; 11: 647-9 (in Chinese).
4. Lu XL, Tao M, Luo JY etal. Epidemiology of alcohol and liver disease. Zhonghua Ganzangbing Zazhi 2002; 10: 467-8.
5. Hunag SL, Dai SQ, Zhang XH etal. An epidemiological survey of alcoholic liver disease in Hunan province. Zhongguo Yishi Zazhi 2005; 7: 426-7 (in Chinese).
6. Wang H, Wang JB. Study on the association of hepatitis virus infection and alcoholic liver cirrhosis (A clinic study on 182 patients with alcoholic liver disease). Baiqiuen Yikedaxue Xuebao 1998; 24: 652-3 (in Chinese).
7. Liu Y, Chi BR. Clinical analysis of 237 cases with alcoholic liver disease. Jilin Yixue 2004; 25: 40-2 (in Chinese).
8. Shen Z, Li YM, Yu CH etal. Risk factors for alcohol-related liver injury in the island population of China: a population-based case-control study. World J Gastroenterol 2008; 14: 2255-61.
9. Becker U, Deis A, Sorensen TI etal. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-9.
10. Kamper-Jorgensen M, Gronbaek M, Tolstrup J etal. Alcohol and cirrhosis: dose-response or threshold effect? J Hepatol 2004; 41: 25-30.
11. Becker U, Gronbaek M, Johansen D etal. Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002; 35: 868-75.
12. Lu XL, Luo JY, Tao M etal. Risk factors for alcoholic liver disease in China. World J Gastroenterol 2004; 10: 2423-6.
13. Sato N, Lindros KO, Baraona E etal. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 2001; 25: 40S-5S.
14. Baraona E, Abittan CS, Dohmen K etal. Gender differences in pharmacokinetics of alcohol. Alcohol Clin Exp Res 2001; 25: 502-7.
15. Wickramasinghe SN, Corridan B, Izaguirre J etal. Ethnic differences in the biological consequences of alcohol abuse: a comparison between south Asian and European males. Alcohol Alcohol 1995; 30: 675-80.
16. Yu C, Li Y, Chen W etal. Genotype of ethanol metabolizing enzyme genes by oligonucleotide microarray in alcoholic liver disease in Chinese people. Chin Med J (Engl) 2002; 115: 1085-7.
17. Borras E, Coutelle C, Rosell A etal. Genetic polymorphism of alcohol dehydrogenase in Europeans: The ADH 2*2 allele decreases the risk for alcoholism and is associated with ADH 3*1. Hepatology 2000; 31: 984-9.
18. Mendenhall C, Roselle GA, Gartside P etal. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635-41.
19. Leevy CM, Moroianu SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005; 9: 67-81.
20. Mezey E. Dietary fat and alcoholic liver disease. Hepatology 1998; 28: 901-5.
21. Williams R. Global challenges in liver disease. Hepatology 2006; 44: 521-6.
22. Zeng MD, Li YM, Chen CW etal. Guidelines for the diagnosis and treatment of alcoholic liver disease. J Dig Dis 2008; 9: 113-6.
23. Yersin B, Nicolet JF, Dercrey H etal. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med 1995; 155: 1907-11.
24. Conigrave KM, Degenhardt LJ, Whitfield JB etal. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002; 26: 332-9.
25. Chen CH, Huang MH, Yang JC etal. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007; 22: 1482-9.
26. Majhi S, Baral N, Lamsal M etal. De Ritis ratio as diagnostic marker of alcoholic liver disease. Nepal Med Coll J 2006; 8: 40-2.
27. Nyblom H, Berggren U, Balldin J etal. High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking. Alcohol Alcohol 2004; 39: 336-9.
28. Sanyal AJ. American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
29. Graif M, Yanuka M, Baraz M etal. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol 2000; 35: 319-24.
30. Ataseven H, Yildrim MH, Yalniz M etal. Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis. J Hepatol 2003; 38 (Suppl 2): A4177.
31. Farrell GC, George J, Pauline de la MH etal, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005; 159-207.
32. Srikureja W, Kyulo NL, Runyon BA etal. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-6.
33. Said A, Williams J, Holden J etal. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903.
34. Carithers RL, Jr, Herlong HF, Diehl AM etal. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-90.
35. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 24-34.
36. Barve A, Khan R, Marsano L etal. Treatment of alcoholic liver disease. Ann Hepatol 2008; 7: 5-15.
37. Robert SOS, Srinivasan D, Arthur JMC etal. Alcoholic liver disease. Hepatology 2010; 51: 307-28.
38. Stickel F, Hoehn B, Schuppan D etal. Review article: nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 2003; 18: 357-73.
39. Mathurin P, Mendenhall CL, Carithers RL Jr etal. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-7.
40. Imperiale TF, O'Connor JB, McCullough AJ. Corticosteroids are effective in patients with severe alcoholic hepatitis. Am J Gastroenterol 1999; 94: 3066-8.
41. Shpilenya LS, Muzychenko AP, Gasbarrini G etal. Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study. Alcohol Clin Exp Res 2002; 26: 340-6.
42. Mato JM, Camara J, Fernandez de PJ etal. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-9.
43. Xing QT, Yuan MB, Gao XM. Observation of the effect of S-adenosyl-L-methionine on alcoholic liver disease. Weichangbingxue He Ganbingxue Zazhi 2002; 11: 239-42 (in Chinese).
44. Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 2005; 65: 2445-61.
45. Hu GP, Liu K, Zhao LS. Polyunsaturated phosphatidylcholine (Essentiale) for alcoholic liver disease and fatty liver: a systematic review. Ganzang 2005; 10: 5-7 (in Chinese).
46. Fang LH, Zhang H. The effect survey of reduced glutathione combined Legalon treatment for alcoholic hepatitis. Ganzang 2004; 8: 181-2 (in Chinese).
47. Zhang QH, Guo SH, Hu DR etal. Effect of domestic glutathione on alcoholic liver disease. Zhonghua Ganzangbing Zazhi 2000; 8: 239-40 (in Chinese).
48. Ma AL, Liu SE, Liu X etal. Comparison of liver histology with alcoholic liver disease after treating with bicyclol and polyene phosphatidylcholine. Linchuang Gandanbing Zazhi 2006; 22: 272-5 (in Chinese).
49. Murray KF, Carithers RL Jr, AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-32.